LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Aktien・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

21.45

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

Max

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.6M -21M
Verkäufe	14M 54M
Gewinnspanne	-39.611
Angestellte	178
EBITDA	-7.7M -26M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	-3.62% downside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1B 2.2B
Vorheriger Eröffnungskurs	21.45
Vorheriger Schlusskurs	21.45

Day One Biopharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Juni 2026, 20:30 UTC

Ergebnisse

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

3. Juni 2026, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

Garth Brooks Considers Sale of Music Catalog, Seeking Roughly $2 Billion -- WSJ

3. Juni 2026, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

Brooks Had Been Entertaining a Deal for a Few Years, Sources Say -- WSJ

3. Juni 2026, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

Brooks Seeking About $2 Billion for Rights to Songs, Recordings, Sources Say -- WSJ

3. Juni 2026, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

Garth Brooks Considering Sale of Music Catalog, Sources Say -- WSJ

2. Juni 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2. Juni 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Juni 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2. Juni 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2. Juni 2026, 23:01 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2. Juni 2026, 23:01 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2. Juni 2026, 23:00 UTC

Akquisitionen, Fusionen, Übernahmen

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2. Juni 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2. Juni 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2. Juni 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. Juni 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2. Juni 2026, 21:00 UTC

Ergebnisse

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. Juni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2. Juni 2026, 20:46 UTC

Ergebnisse

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. Juni 2026, 20:38 UTC

Ergebnisse

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2. Juni 2026, 20:21 UTC

Ergebnisse

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. Juni 2026, 20:12 UTC

Ergebnisse

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks 3Q Product Rev $594M

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

Peer-Vergleich

Kursveränderung

Day One Biopharmaceuticals Inc Prognose

Kursziel

By TipRanks

-3.62% Nachteil

12-Monats-Prognose

Durchschnitt 20.75 USD -3.62%

Hoch 21.5 USD

Tief 17 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Day One Biopharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

7 ratings

Buy

Halten

Sell

Basierend auf 7 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Day One Biopharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.